↓ Skip to main content

A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients

Overview of attention for article published in BMC Cancer, October 2011
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

wikipedia
1 Wikipedia page

Citations

dimensions_citation
55 Dimensions

Readers on

mendeley
59 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients
Published in
BMC Cancer, October 2011
DOI 10.1186/1471-2407-11-432
Pubmed ID
Authors

Mark J McKeage, Yongchuan Gu, William R Wilson, Andrew Hill, Karen Amies, Teresa J Melink, Michael B Jameson

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 59 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 59 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 12 20%
Researcher 9 15%
Student > Ph. D. Student 8 14%
Student > Master 7 12%
Student > Postgraduate 3 5%
Other 9 15%
Unknown 11 19%
Readers by discipline Count As %
Medicine and Dentistry 16 27%
Biochemistry, Genetics and Molecular Biology 11 19%
Agricultural and Biological Sciences 6 10%
Pharmacology, Toxicology and Pharmaceutical Science 4 7%
Chemistry 4 7%
Other 6 10%
Unknown 12 20%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 July 2016.
All research outputs
#7,486,178
of 22,881,154 outputs
Outputs from BMC Cancer
#2,069
of 8,326 outputs
Outputs of similar age
#46,083
of 135,994 outputs
Outputs of similar age from BMC Cancer
#28
of 95 outputs
Altmetric has tracked 22,881,154 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,326 research outputs from this source. They receive a mean Attention Score of 4.3. This one has gotten more attention than average, scoring higher than 68% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 135,994 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 95 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.